Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eupraxia Pharmaceuticals ( (TSE:EPRX) ) has shared an update.
On April 21, 2026, Eupraxia Pharmaceuticals reported 36-week data from the highest dose cohort of its ongoing Phase 1b/2a RESOLVE trial of EP-104GI in adults with eosinophilic esophagitis, showing strong and durable improvements in tissue health and swallowing symptoms after a single esophageal wall injection. Patients in the top-dose Cohort 9 (n=3) recorded the largest reductions in histologic scores and peak eosinophil counts across all cohorts, a 66% rate of sustained clinical remission from weeks 8 to 36, and a favourable safety profile with no drug-related serious adverse events, adrenal or glucose issues, or cases of oropharyngeal candidiasis, reinforcing the drug’s potential and supporting ongoing enrollment in the randomized Phase 2b portion of RESOLVE.
The nine-month findings underscore the promise of Eupraxia’s localized steroid delivery approach in a disease area with growing prevalence and limited treatment options, potentially strengthening the company’s position in inflammatory gastrointestinal therapeutics. With EP-104GI advancing through RESOLVE and prior positive results from its knee osteoarthritis program, Eupraxia is building a clinical portfolio that could enhance its standing among specialty biotech investors and clinicians focused on chronic inflammatory conditions.
The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.
Spark’s Take on EPRX Stock
According to Spark, TipRanks’ AI Analyst, EPRX is a Neutral.
The score is held back primarily by the pre-revenue model with widening losses and rising cash burn, despite a notably improved, low-debt balance sheet. Technical indicators also reflect weak near-term momentum, and valuation signals are limited by negative earnings and lack of dividend support.
To see Spark’s full report on EPRX stock, click here.
More about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company developing locally delivered, extended-release therapies for high unmet medical needs using its proprietary Diffusphere micro-sphere technology. Its pipeline targets pain and inflammatory gastrointestinal diseases, including eosinophilic esophagitis, and may extend to oncology, infectious disease and other indications, with candidates designed to improve safety, tolerability and duration of effect versus existing drugs.
Average Trading Volume: 83,110
Technical Sentiment Signal: Buy
Current Market Cap: C$622.5M
For a thorough assessment of EPRX stock, go to TipRanks’ Stock Analysis page.